-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVie’s Bezisterim Shows Trend Toward Symptom Improvement in Phase 2 Long COVID Trial

PUBT·10/26/2026 12:10:47
Listen to the news
BioVie’s Bezisterim Shows Trend Toward Symptom Improvement in Phase 2 Long COVID Trial
  • BioVie will present Phase 2 ADDRESS-LC results for bezisterim in Long COVID on November 5, 2026, at the RECOVER-TLC workshop.
  • Bezisterim showed a consistent trend toward improvement versus placebo across most patient-reported symptoms and objective measures.
  • Patients with greater baseline symptom severity benefited most, with statistically significant improvements in measures corresponding to their most pronounced symptoms.
  • Safety and tolerability were similar to placebo.
  • The findings provide a foundation for designing a confirmatory Phase 3 study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800PRIMZONEFULLFEED9852798) on October 26, 2026, and is solely responsible for the information contained therein.